Serum Neurofilament-light Chain and GFAP Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis (NCT03981003)
Serum Neurofilament-light Chain and Glial Fibrillary Acidic Proten (GFAP) Levels in Patients From the OFSEP Cohort at Different Landmarks of Multiple Sclerosis
🩺 Plain-English Summary (8th-Grade Level)
The investigators hypothesize that serum neurofilament-light chain (NfL) levels can provide information about the level of activity and progression of Multiple Sclerosis at different stages and landmarks of the disease. In addition, Glial Fibrillary Acidic Protein (GFAP) has also been identified as another serum biomarker of disability in MS.
Who can join: Review the eligibility criteria below.
Location: CHU d'Amiens — Amiens
Age range: 15 Years
🧪 Interventions in This Study
- Blood sample (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- CHU d'Amiens — Amiens,
- CHU de Besancon — Besançon,
- CHU de Bordeaux — Bordeaux,
- CHU de Caen — Caen,
- CHU de Clermont Ferrand — Clermont-Ferrand,
- Hopital Henri Mondor — Créteil,
- CHU de Dijon — Dijon,
- CHU de Grenoble — Grenoble,
- CHU de Lille — Lille,
- CHU de Limoges — Limoges,
- CHU de Lyon — Lyon,
- Hopital Timone — Marseille,
- CHU de Montpellier — Montpellier,
- CHU de Nancy — Nancy,
- CHU de Nice — Nice,
- CHU de Nimes — Nîmes,
- Fondation Rothschild — Paris,
- Hopital Pitie Salpetriere — Paris,
- Hopital Saint Antoine — Paris,
- CH de Poissy — Poissy,
- CHU de Potiers — Potiers,
- CHU de Rennes — Rennes,
- CHU de Rouen — Rouen,
- CHU de Saint Etienne — Saint-Etienne,
- CHU de Strasbourg — Strasbourg,
📞 Contact the Study Coordinator
Phone: +33.(0)4.66.68.32.61
Email: eric.thouvenot@chu-nimes.fr
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Sclerosis
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis — Birmingham, Alabama
- MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience — New Orleans, Louisiana
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Phoenix, Arizona
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Carlsbad, California
- The Synergistic Effects of AIH and FES in Persons With MS — Chicago, Illinois
- A Health Action Process Approach Online Intervention for People With Multiple Sclerosis — Champaign, Illinois
Explore by condition: All Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.